Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Allergan has signed a lease for big chunk of office space in Texas, according to the Austin Business Journal, keeping quiet on its plans as it slashes jobs around the globe.
European venture outfit LSP (Life Sciences Partners) has raised $100 million toward a new biotech fund, setting out to stake a dozen or so innovators in drugs, devices and diagnostics.
Portola Pharmaceuticals' antidote to Big Pharma's latest crop of blockbuster blood thinners hit the mark in its first Phase III trial, clearing the way for an FDA submission next year.
Flush with cash from its high-profile collaborators, FibroGen is plotting a $120 million IPO to help bankroll a stable of unpartnered drugs, including a promising lung treatment with huge market potential.
GlaxoSmithKline is expanding its efforts to encourage research into bioelectronic medicine, putting up $5 million to support R&D projects around the world.
Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.
Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions.
Catalyst Pharmaceutical Partners is heralding positive late-stage results for its lead drug, planning to make its case to the FDA in hopes of winning approval for a much-scrutinized orphan treatment.
Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs.
After a series of painful rejections, partners Alimera Sciences and pSivida have finally convinced the FDA to approve the eye drug Iluvien, sending each company's shares roaring on some renewed optimism for the long-delayed treatment.